-
Recombinant KMT2D (MLL2)-SET protein
Recombinant KMT2D (MLL2)-SET protein
- 中文名称：
- Recombinant KMT2D (MLL2)-SET protein
- 英文名称：
- Recombinant KMT2D (MLL2)-SET protein
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA59671
- 规格：
- 0.05 mg|1 mg|2x1 mg|3x1 mg|4x1 mg
- 保存建议：
- Recombinant proteins in solution are temperature sensitive and must be stored at -80 degree C to prevent degradation. Avoid repeated freeze/thaw cycles and keep on ice when not in storage.
Shipping Temp: Dry Ice
- 货期：
- 6-8周
- 纯度：
- The recombinant protein is >= 80% pure by SDS-PAGE.
- 产品形式：
- Recombinant KMT2D (MLL2)-SET protein was expressed in E Coli cells and supplied in 25mM Tris pH8.0, 300mM NaCl, 5% glycerol, 0.04% Triton X-100.
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 说明书：
Short Description: The peptide corresponding to amino acids 5355-5537 of the MLL2 protein (accession number NP_003473.3) was expressed in E Coli. The peptide contains the SET domain of MLL2 that is responsible for methyltransferase activity. Recombinant MLL2-SET contains an N-terminal GST-Tag with a molecular weight of 47.6 kDa. Myeloid/lymphoid or mixed-lineage leukemia 2 (MLL2) is a Trithorax-group protein that function collectively to promote gene expression. MLL2 is a histone methyltransferase that methylates the Lysine 4 position of histone H3. In particular, the SET domain is a conserved C-terminal domain that characterizes proteins of the MLL (mixed-lineage leukemia) family. The SET domain is responsible for its histone methyltransferase activity which mediates chromatin modifications associated with epigenetic transcriptional activation. H3K4 methylation represents a specific epigenetic tag for transcriptional activation. MLL2 is part of a large protein complex called ASCOM, which has been shown to be a transcriptional regulator of the b-globin and estrogen receptor genes. Mutations in this gene have been shown to be a cause of Kabuki syndrome. Recombinant MLL2-SET protein can be used for enzyme kinetics and inhibitor screening studies.
Background: KMT2D (MLL2)-SET (Myeloid/lymphoid or mixed-lineage leukemia 2) is a Trithorax-group protein that function collectively to promote gene expression. KMT2D (MLL2)-SET is a histone methyltransferase that methylates the Lysine 4 position of histone H3. In particular, the SET domain is a conserved C-terminal domain that characterizes proteins of the MLL (mixed-lineage leukemia) family. The SET domain is responsible for its histone methyltransferase activity which mediates chromatin modifications associated with epigenetic transcriptional activation. H3K4 methylation represents a specific epigenetic tag for transcriptional activation. KMT2D (MLL2)-SET is part of a large protein complex called ASCOM, which has been shown to be a transcriptional regulator of the b-globin and estrogen receptor genes. Mutations in this gene have been shown to be a cause of Kabuki syndrome.
